Conversely to our results, the literature shows that a lower OPRM1 gene expression may condition higher OUD rates in patients with long-term opioid use, such as cancer-pain patients [31], subjects in methadone programmes [32], or former heroin addicts [28]. The gene discussed is OPRM1; the disease is cancer.